Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00131326 · ClinicalTrials.gov registry record · Phase 3
A Study of the Safety and Efficacy of Synvisc and Depo-Medrol in Patients With Osteoarthritis of the Hip
A Phase 3 study, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00131326: Completed Phase 3 study, sponsored by Genzyme, a Sanofi Company.
NCT00131326 is a Phase 3 study that has completed, run by Genzyme, a Sanofi Company. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00131326, a Phase 3 study, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
This is a clinical study to investigate the safety and efficacy of Synvisc and Depo-Medrol in treating patients with osteoarthritis (OA) of the hip.
Interventions
- DEVICE Synvisc (hylan G-F 20)
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-11 |
| Est. Completion | 2006-04 |
| Phase | Phase 3 |
What the finished NCT00131326 record still lists
NCT00131326 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Synvisc (hylan G-F 20) is the first listed.
NCT00131326 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00131326 about?
NCT00131326 is a clinical study titled "A Study of the Safety and Efficacy of Synvisc and Depo-Medrol in Patients With Osteoarthritis of the Hip". This is a clinical study to investigate the safety and efficacy of Synvisc and Depo-Medrol in treating patients with osteoarthritis (OA) of the hip.
What is the current status of trial NCT00131326?
This trial is currently completed. It is a Phase 3 study. The study started on 2003-11. Estimated completion is 2006-04.
What interventions are being tested in trial NCT00131326?
The interventions under investigation include: Synvisc (hylan G-F 20) (DEVICE).
Who is sponsoring clinical trial NCT00131326?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia